Life Sciences
Oxford Biomedica to increase production of AstraZeneca COVID-19 vaccine
AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021.
Oxford’s Vaccitech completes IPO on Nasdaq and raises $110.5m
The Oxford-based clinical-stage biopharmaceutical company that co-invented a COVID-19 vaccine is a spin-out from Oxford University’s Jenner Institute.
Sense raises $50m Series B funding for instrument-free product platform
The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare.
Oxford Endovascular raises $10m to develop its origami engineered medical device
The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study.
Exscientia announces first AI-designed immuno-oncology drug in clinical trials
The company’s technologies and drug-hunting expertise now responsible for the world’s first and second AI-designed drugs to enter Phase I testing.
WuXi AppTec completes acquisition of Oxford-based OXGENE
This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
Sensyne Health licenses MagnifEye technology to Excalibur Healthcare
Excalibur will integrate MagnifEye into its lateral flow products for global marketing to customers in both the public and private sectors.
Sensyne Health has launched AI algorithm for real-time patient management
Co-developed with Chelsea and Westminster Hospital, this is the first in a series of operational AI algorithms to be launched commercially and offered across the UK and US health systems.
Immunocore closes $75m Series C private financing round
Led by an existing investor, the funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma.
Enara Bio enters strategic collaboration with Boehringer Ingelheim
The strategic collaboration and licensing agreement will research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform.
Tool identifies COVID-19 patients at highest risk of deterioration
The online tool, made freely available to NHS doctors, could support clinicians’ decision making – helping to improve patient outcomes and ultimately save lives.
Oxford-based biotech Theolytics raises $6.8m Series A round funding
The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).